Under the Hereditary Angioedema Microscope: Navigating the Latest Advances in HAE at AAAAI 2024

Join AAAAI president Dr. Bernstein and colleagues, Dr. Lumry and Dr. Riedl, for this engaging LIVE social media event as they discuss the latest developments in Hereditary Angioedema at AAAAI 2024. They will spotlight key studies poised to revolutionize HAE management paradigms from tailored treatment to address patients’ unmet needs to insights about evolving therapy.
Marc Riedl, MD, MS
Professor of Medicine
Clinical Director - US HAEA Angioedema Center
Clinical Service Chief - Division of Allergy & Immunology
University of California, San Diego
San Diego, CA
Mark Riedl, MD, MS has disclosed:
Consultant/Advisor: AstraZeneca; BioCryst Pharm., Inc.; BioMarin Pharm., Inc.; Celldex Therapeutics, Inc.; CSL Behring; Cycle Pharma; Grifols; Intellia; KalVista Pharm.; Pfizer, Inc.; Pharming Group NV; Pharvaris; Sanofi-Regeneron; Takeda
Speakers Bureau for: CSL Behring; Grifols; Pharming Group NV; Takeda
Research funding: BioCryst Pharm., Inc.; BioMarin Pharm., Inc.; CSL Behring; Ionis; KalVista Pharm.; Pharvaris; Takeda
Jonathan A. Bernstein, MD
Professor of Clinical Medicine
University of Cincinnati College of Medicine
Division of Rheumatology, Allergy and Immunology
Partner of Bernstein Allergy Group and Bernstein Clinical Research Center
Cincinnati, OH
Jonathan A. Bernstein, MD has disclosed:
Consultant/Advisor: Amgen Inc.; AstraZeneca; BioCryst Pharm., Inc.; BioMarin Pharm., Inc.; Blueprint Medicine; Celldex Therapeutics, Inc.; Cogent; CSL Behring; Genentech; GlaxoSmithKline; Ionis; Johnson & Johnson; KalVista Pharm.; Novartis; Roche; Sanofi-Regeneron; Shire; Takeda;
Research funding: Amgen Inc.; AstraZeneca; BioCryst Pharm., Inc.; BioMarin Pharm., Inc.; Blueprint Medicines; Celldex Therapeutics, Inc.; Cogent; CSL Behring; Genentech; GlaxoSmithKline; Ionis; Johnson & Johnson; KalVista Pharm.; Novartis; Roche; Sanofi-Regeneron.; Shire; Takeda
Contracted researcher:: Amgen Inc.; AstraZeneca; BioCryst Pharm., Inc.; BioMarin Pharm., Inc.; Blueprint Medicines; Celldex Therapeutics, Inc.; Cogent; CSL Behring; Genentech; GlaxoSmithKline; Ionis; Johnson & Johnson; KalVista Pharm.; Merck; Novartis; Roche; Sanofi-Regeneron; Shire; Takeda
William R. Lumry, M.D.
Clinical Professor of Internal Medicine
University of Texas Southwestern Medical School
Owner Allergy & Asthma Specialists and AARA Research Center
Dallas, TX
William R. Lumry, MD has disclosed:
Consultant/advisor: AstraZeneca; BioCryst Pharm., Inc; BioMarin Pharm., Inc; CSL Behring; CVS; Express Scripts; Fresenius Kabi; Intellia; KalVista Pharm.; Optum; Pharming Group NV; Pharvaris; Shire; Takeda
Speakers Bureau for: AstraZeneca; BioCryst Pharm., Inc; CSL Behring; GlaxoSmithKline; Grifols; Optinose; Pharming Group NV; Sanofi-Regeneron.; Shire; Takeda
Research funding: AstraZeneca; BioMarin Pharm., Inc; CSL Behring; Grifols; Ionis; KalVista Pharm.; Shire; Takeda; Teva
Contracted researcher: AstraZeneca; BioMarin Pharm., Inc.; CSL Behring; Grifols; Ionis; KalVista Pharm.; Shire; Takeda; Teva